Massimo Giachetti/iStock Editorial via Getty Images
EOM Pharmaceuticals (EOM) (OTCPK:IMUC) has withdrawn its filing to uplist its shares to Nasdaq and raise around $15M through a public offering.
EOM shares are currently traded OTC under the symbol IMUC. The company had sought to uplist the shares to Nasdaq under the symbol EOM.
The biotech company, which has two drugs in Phase 2 development, had originally filed for the offering in June 2022, seeking around $25M. It downsized the amount to $15M in December.
In its original filing, EOM said that it was primarily funded by the family of its chairman and chief operating officer, Eli Goldberger. The company was formerly known as Intercellular Therapeutics.
More on EOM:
EOM Pharmaceutical Files For $25 Million IPO Uplisting To Nasdaq
Eom Pharmaceuticals files for possible $25M IPO, changing name from Intercellular Therapeutics
EOM Pharmaceuticals files to uplist to Nasdaq